What is HC Wainwright’s Estimate for AXSM FY2024 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a report released on Tuesday, January 21st. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($4.58) per share for the year, up from their prior forecast of ($4.60). HC Wainwright has a “Buy” rating and a $180.00 price objective on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.73) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q4 2024 earnings at ($0.92) EPS, Q1 2025 earnings at ($0.85) EPS, Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at $0.38 EPS and FY2025 earnings at ($1.37) EPS.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The business had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. During the same quarter in the previous year, the business posted ($1.32) EPS.

A number of other equities research analysts have also recently commented on AXSM. Cantor Fitzgerald reissued an “overweight” rating and set a $121.00 target price on shares of Axsome Therapeutics in a research report on Thursday, December 12th. Mizuho decreased their price objective on Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday, December 31st. Robert W. Baird boosted their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Royal Bank of Canada increased their price target on Axsome Therapeutics from $130.00 to $131.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. Finally, StockNews.com upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, Axsome Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $130.69.

Axsome Therapeutics Stock Performance

Shares of NASDAQ AXSM opened at $102.27 on Thursday. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $105.00. The stock’s fifty day simple moving average is $92.32 and its two-hundred day simple moving average is $89.80.

Institutional Trading of Axsome Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. acquired a new position in Axsome Therapeutics in the 2nd quarter valued at $27,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Axsome Therapeutics during the second quarter worth about $47,000. R Squared Ltd purchased a new position in Axsome Therapeutics during the fourth quarter worth about $64,000. KBC Group NV lifted its position in Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after purchasing an additional 385 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after purchasing an additional 318 shares in the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.